AI assistant
ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2012
May 10, 2012
33882_dirs_2012-05-10_16c5b006-6eb6-4a89-8649-35c83149fdef.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2012-05-08
Reporting Person: BURRIS MICHELLE (CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-05-08 | Stock Option (right to buy) | $13.00 | A | 15000 | Acquired | 2022-05-08 | Common (15000) | Direct |
| 2012-05-08 | Restricted Stock Units | $ | A | 7500 | Acquired | 2016-01-31 | Common (7500) | Direct |
| 2012-05-08 | Restricted Stock Units | $ | A | 17500 | Acquired | 2014-04-30 | Common (17500) | Direct |
Footnotes
F1: The options vest in monthly installments over 48 months commencing January 1, 2012.
F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's Common stock.
F3: The restricted stock units vest 25% annually on the later of: (i) each anniversary of January 1, 2012; and (ii) the first day thereafter during which the issuer's trading window is open.
F4: The restricted stock units vest 100% on the later of (i) achievement of both the successful enrollment and release of data from certain clinical trials, and (ii) the first trading day thereafter on which the issuer's trading window is open.